Literature DB >> 2651223

Mechanism(s) of bioreductive activation. The example of diaziquone (AZQ).

P L Gutierrez1.   

Abstract

Bioreduction in the activation of diaziquone (2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone) has been investigated by exploring its reduction by whole cells, rat liver microsomes and purified enzymes. The mechanism of bioreduction was further investigated by exploring the chemical and electrochemical reduction of diaziquone as well as its photochemistry. Reduced diaziquone (by several means) was then tested for activity against parent compound. It appears that reduced diaziquone in most cases is more active than the oxidized form. Diaziquone redox cycles, but it is easily reduced to the hydroquinone which oxidizes to the semiquinone yielding free radicals under aerobiosis. The most probable mechanism of action is that of bioreductive alkylation where the alkylating aziridines are protonated after reduction facilitating the opening of the aziridine rings and thus alkylation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651223     DOI: 10.1016/0891-5849(89)90087-7

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  4 in total

1.  Synthesis, molecular docking and antibacterial evaluation of new 1,4-naphthoquinone derivatives contains carbazole-6,11-dione moiety.

Authors:  P Ravichandiran; D Premnath; S Vasanthkumar
Journal:  J Chem Biol       Date:  2014-06-12

2.  Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase.

Authors:  I D Ordoñez; E Cadenas
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

3.  In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.

Authors:  R M Phillips; P B Hulbert; M C Bibby; N R Sleigh; J A Double
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

4.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.